The Institute of Liver Disease & Transplantation, Dr. Rela Institute & Medical Centre, Bharat Institute of Higher Education & Research, Chennai, India.
Paediatric Intensive Care Unit, Kanchi Kamakoti Childs Trust Hospital, Chennai, India.
J Gastrointest Cancer. 2021 Sep;52(3):1165-1168. doi: 10.1007/s12029-021-00627-9. Epub 2021 Mar 22.
Posttransplant lymphoproliferative disease (PTLD) is the most common malignant complication after solid organ transplantation. Gastrointestinal involvement as the presentation in early PTLD can occur in 25-30% of pediatric liver transplant recipients and can be the only system involved in 20%. Recurrent gastrointestinal perforation due to resolution of PTLD is an extremely rare complication. We report a 13-month-old male child diagnosed with PTLD, treatment of which lead to recurrent intestinal perforations. The child presented with gastrointestinal bleed 5 months after living donor liver transplantation for biliary atresia. Evaluation was suggestive of PTLD and biopsy confirmed diffuse large B-cell lymphoma. Positron emission tomography scan showed diffuse involvement of small intestine and ileum. Tacrolimus was withdrawn abruptly following diagnosis of PTLD as there was associated renal impairment. Child developed six episodes of small intestinal perforations over 3 weeks which required multiple laparotomies with closure of perforation and/or small bowel resection. Complete remission was achieved six months after diagnosis with cessation of immunosuppression alone and child is alive at 48 months follow-up without any recurrence. To avoid bowel perforation and complications related to tumor necrosis, immunosuppression reduction in PTLD should be gradual while carefully monitoring Epstein-Barr virus levels, tumor response, graft function, and general health status of the patient.
移植后淋巴组织增生性疾病(PTLD)是实体器官移植后最常见的恶性并发症。胃肠道受累作为早期 PTLD 的表现,可发生在 25-30%的小儿肝移植受者中,20%的患者可仅累及胃肠道。PTLD 缓解后反复发作的胃肠道穿孔是一种极其罕见的并发症。我们报告了 1 例 13 个月大的男性患儿,诊断为 PTLD,治疗导致反复发作的肠穿孔。患儿在胆道闭锁行活体供肝移植后 5 个月出现胃肠道出血。评估提示为 PTLD,活检证实为弥漫性大 B 细胞淋巴瘤。正电子发射断层扫描显示小肠和回肠弥漫受累。PTLD 诊断后立即停用他克莫司,因为伴有肾功能损害。患儿在 3 周内发生 6 次小肠穿孔,需要多次剖腹手术以闭合穿孔和/或小肠切除术。单独停用免疫抑制剂 6 个月后达到完全缓解,患儿在 48 个月的随访中无任何复发,仍然存活。为避免肠穿孔和与肿瘤坏死相关的并发症,PTLD 时应逐渐减少免疫抑制,同时仔细监测 EBV 水平、肿瘤反应、移植物功能和患者的整体健康状况。